Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

768P - Does dose to subventricular zone act as a predictor of overall survival and progression free survival in glioblastoma multiforme (GBM)?

Date

07 Dec 2024

Session

Poster Display session

Presenters

Neha Lall

Citation

Annals of Oncology (2024) 35 (suppl_4): S1679-S1697. 10.1016/annonc/annonc1699

Authors

N. Lall1, S. Choudhary1, L. Aggrawal1, A. Kumar2

Author affiliations

  • 1 Radiotherapy & Radiation Medicine, Institute of Medical Sciences, Banaras Hindu University, 221005 - Varanasi/IN
  • 2 Neurology, Institute of Medical Sciences, Banaras Hindu University, 221005 - Varanasi/IN

Resources

This content is available to ESMO members and event participants.

Abstract 768P

Background

Despite best management strategies glioblastoma (GBM) survival remains poor. Cancer stem cells may be possible in initiation and recurrence of GBM. They are believed to originate from stem cells in the subventricular zone (SVZ). In this study, we retrospectively collected the data using institutional medical records and analyzed the relationship of SVZ dose to survival.

Methods

We included 48 GBM patients treated between 2017 to March 2024. Post tumor resection, 34 patients received radiotherapy to dose 59.4-60 Gray in 30 fractions and 14 received 40 Gray in 15 fractions with concurrent and adjuvant six cycles of temozolomide. Ipsilateral and contralateral SVZ were delineated as 5 mm along lateral wall of lateral ventricles. The effect of high SVZ dose on OS and PFS were determined using Log rank test, Kaplan Meier survival curve and Cox proportional hazard models. The variables for multivariate analysis were pre-radiotherapy KPS, ipsilateral and contralateral SVZ dose, tumor brain volume ratio and tumor size group.

Results

The mean age group 43 years, pre-radiotherapy KPS < 80 was in 24 (50%). Mean ipsilateral SVZ max dose, contralateral SVZ max dose and mean tumor brain volume ratio were 54.47 Gray, 49.53 Gray and 31.52 % respectively. The mean OS and PFS were 16.2 and 13.8 months. Median OS was significantly more in tumor brain volume ratio < 29 % (31.7 vs 14.2 months), ipsilateral SVZ max dose >49 Gray (26.3 vs 15.9 months) and contralateral SVZ max dose >49 Gray (26.3 vs 14.9 months). Median PFS was significantly more in tumor size < 4 cm (26.3 vs 14.9 months), ipsilateral SVZ max dose >49 Gray (21.8 vs 7.4 months), contralateral SVZ max dose >49 Gray (23.2 vs 14.2 months). On multivariate analysis, pre-radiotherapy KPS >80, ipsilateral SVZ max dose >49 Gray and tumor brain volume ratio < 29 % remained a statistically significant predictor for improved OS. While pre-radiotherapy KPS >80, tumor size < 4cm, ipsilateral and contralateral SVZ max dose > 49 Gray were statistically significant predictor for improved PFS.

Conclusions

High Ipsilateral SVZ max dose (>49 Gray) and tumor brain ratio < 29 % are associated with better OS. High Ipsilateral and contralateral SVZ max dose (>49 Gray) is associated with better PFS in GBM patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.